View all news

GXAI: Gaxos.AI Reduces Marketing Spend and Still Grows

11/17/2026

By Lisa Thompson

NASDAQ: GXAI

READ THE FULL GXAI RESEARCH REPORT

Gaxos.AI (NASDAQ: GXAI) reported Q3 with slightly lower revenues and losses than we expected. Revenues were up 465% to $2.8 million and up sequentially from $2.6 million in Q2. Losses decreased as the company pulled back from spending on advertising as rates went up due to seasonality, and management determined that those prices would not result in profitable outcomes. They refuse to grow revenues at all costs. We expect further pull back in spending in Q4 and possibly lower sequential revenues. In Q1, we expect the company to return to its previous spend as ad rates go back down. Currently, its biggest seller in the health business is Naltrexone, a prescription medication classified as an opioid antagonist. It is approved by the FDA to help treat alcohol use disorder (AUD) and opioid use disorder. It is popular because it is non-addictive, curbs cravings, supports alcohol moderation without sickness, costs little, and is easily prescribed via telehealth. It also helps manage weight loss and chronic pain.

The company is considering adding other products to RNK Health’s lineup. One is erectile dysfunction medicine, but possibly more promising are new peptides. On October 28, 2026, HHS issued a policy allowing licensed compounding pharmacies to prepare six peptides under specific safeguards. Two of them, BPC-157 and TB-500, are part of the “Wolverine Stack”—to accelerate physical recovery. The name comes from the Marvel superhero and is heavily promoted in bodybuilding, biohacking, and sports recovery circles for treating tendon, ligament, muscle, and joint injuries. Before this policy change, users had to buy these products through unregulated online "research chemical" websites and foreign underground labs. Now legal sources are beginning to enter the market.

We are adjusting our Q4 numbers to account for spending and seasonality. We are encouraged by the continued growth and lower cash burn this quarter. With $13 million in cash, the company has considerable runway, burning between $1 and $2 million in cash per quarter. It should be exiting the year at a $10 million run rate, having grown from nothing in two years. We are keeping 2027 estimates virtually as is. The stock trades at a negative enterprise value of $7.4 million, using $13 million in cash plus short-term investments and a 13.8 million share count. We believe the stock could be worth $3.70, based on $14 million in revenue in 2027 at a blended EV-to-Sales multiple, in line with its peers.

SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you. Please visit our website for additional information on Zacks SCR.

DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives payments totaling a maximum fee of up to $50,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.

Multimedia Files:

Categories: Press Releases
View all news